CD6(分化簇 6)是 T 细胞和 B 细胞亚群的表面糖蛋白,属于清道夫受体富含半胱氨酸 (SRCR) 糖蛋白超家族。CD166、ALCAM 和 CD318 是 CD6 的配体。CD6 与其配体相互作用,在胸腺细胞发育、T 细胞活化和免疫反应中起关键作用。CD6 在结构上与 CD5 相似。CD6 和 CD5 被视为共刺激受体,可放大 T 细胞受体 (TCR) 依赖性活化。CD6 是治疗自身免疫性疾病的重要靶点,例如抗 CD6 单克隆抗体 (mAb)[1][2]。
CD6 (Cluster of Differentiation 6) is a surface glycoprotein of T cells and a subset of B cells, and belongs to the superfamily of scavenger receptor cysteine-rich (SRCR) glycoproteins. CD166, ALCAM and CD318 are ligands for CD6. CD6 interacts with its ligands and plays a key role in thymocyte development, T cell activation and immune responses. CD6 is structurally similar to CD5. CD6 and CD5 have been regarded as co-stimulatory receptors that amplify T-cell receptor (TCR)-dependent activation. CD6 is an important target for therapy against autoimmune diseases, such as Anti-CD6 monoclonal antibody (mAb)[1][2].
Itolizumab(抗人 CD6 重组抗体)是一种靶向 CD6 细胞外 SRCR 远端结构域 1 的人源化重组抗 CD6 单克隆抗体(MAb),可减少 T 细胞增殖并抑制 INF-γ、TNFα 和 IL-6 等促炎细胞因子的产生,可用于银屑病、类风湿性关节炎(RA)和 COVID-19 的研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号